- Home
- PG vs ABBV Comparison
PG vs ABBV Comparison
Compare PG & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PG | ABBV |
|---|---|---|
| Founded | 1837 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 369.9B | 400.9B |
| IPO Year | 2014 | 2012 |
Fundamental Metrics
Financial Performance| Metric | PG | ABBV |
|---|---|---|
| Price | $165.20 | $228.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 18 |
| Target Price | $170.86 | ★ $246.29 |
| AVG Volume (30 Days) | ★ 10.2M | 6.4M |
| Earning Date | 04-23-2026 | 04-13-2026 |
| Dividend Yield | 2.63% | ★ 3.08% |
| EPS Growth | ★ 8.14 | N/A |
| EPS | ★ 3.73 | 2.36 |
| Revenue | ★ $84,284,000,000.00 | $61,160,000,000.00 |
| Revenue This Year | $5.84 | $11.90 |
| Revenue Next Year | $2.65 | $8.44 |
| P/E Ratio | ★ $43.10 | $95.26 |
| Revenue Growth | 0.29 | ★ 8.57 |
| 52 Week Low | $137.62 | $164.39 |
| 52 Week High | $179.99 | $244.81 |
Technical Indicators
Market Signals| Indicator | PG | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 72.51 | 55.90 |
| Support Level | $156.54 | $219.72 |
| Resistance Level | $170.99 | $229.94 |
| Average True Range (ATR) | 3.28 | 6.42 |
| MACD | 0.24 | 0.58 |
| Stochastic Oscillator | 99.16 | 80.15 |
Price Performance
Historical ComparisonAbout PG Procter & Gamble Company (The)
Since its founding in 1837, Procter & Gamble has become one of the world's largest consumer product manufacturers, with annual sales of nearly $85 billion. It operates with a lineup of leading brands, including more than 20 that generate north of $1 billion each in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. Sales outside its home turf represent just more than half of the firm's consolidated total.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.